In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles. by Chou, Meng-Ing et al.
In vitro and in vivo targeted delivery of IL-10 interfering
RNA by JC virus-like particles.
Meng-Ing Chou, Yu-Fan Hsieh, Meilin Wang, Jinghua Chang, Deching Chang,
Moncef Zouali, Gregory Tsay
To cite this version:
Meng-Ing Chou, Yu-Fan Hsieh, Meilin Wang, Jinghua Chang, Deching Chang, et al.. In vitro
and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles.. Journal
of Biomedical Science, BioMed Central, 2010, 17 (1), pp.51. <10.1186/1423-0127-17-51>.
<inserm-00663735>
HAL Id: inserm-00663735
http://www.hal.inserm.fr/inserm-00663735
Submitted on 27 Jan 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Chou et al. Journal of Biomedical Science 2010, 17:51
http://www.jbiomedsci.com/content/17/1/51
Open AccessR E S E A R C H© 2010 Chou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
ResearchIn vitro and in vivo targeted delivery of IL-10 
interfering RNA by JC virus-like particles
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Abstract
Background: RNA interference (RNAi) is a powerful tool to silence gene expression post-transcriptionally. Delivering 
sequences of RNAi in vivo remains a problem. The aim of this study was to use JC virus (JCV) virus-like particles (VLPs) as 
a vector for delivering RNAi in silencing the cytokine gene of IL-10.
Methods: JCV VLPs were generated by recombinant JCV VP1 protein in yeast expression system. DNA fragment 
containing IL-10 shRNA was packaged into VLPs by osmotic shock.
Results: In RAW 264.7 cells, IL-10 shRNA was found to reduce IL-10 expression by 85 to 89%, as compared with VLPs 
alone. IL-10 shRNA did not cross-react with TNF-alpha mRNA or influence the expression of TNF-alpha. In BALB/c mice 
IL-10 shRNA could reduce 95% of IL-10 secretion. Surprisingly, it also down regulated TNF-alpha expression.
Conclusions: We show for the first time that JCV VLPs empty capsids are competent vectors to deliver RNAi and are 
nontoxic to cells, suggesting that JCV VLPs is an efficient agent to deliver RNAi in both murine macrophage cells and 
BALB/c mice. This system provides an efficient means for delivering the RNAi for gene therapy purposes.
Background
Transfection of RNA interference (RNAi) into living cells
is a major technique in studying the biological function of
genes and for their potential treatment of human dis-
eases. There are considerable excitements about its
potential therapeutic applications in human diseases [1-
3]. RNAi offers the prospects of higher specificity, lower
immunogenicity, and greater disease modification than
current antibody therapies for systemic autoimmune dis-
eases (AID) such as systemic lupus erythematosus (SLE).
The major challenge in turning RNAi into an effective
therapeutic strategy is the delivery system.
JC virus (JCV), a human polyomavirus, belongs to the
polyomaviridae. The JC virion contains three capsid pro-
teins (VP1, VP2 and VP3) and a viral mini chromosome.
VP1 is the major capsid protein constituting approxi-
mately 75% of the total proteins. Chang et al. [4] found
that JCV VP1 could be transported into the nucleus and
self-assembled to form capsid-like particles (VLPs) simi-
lar to the natural empty capsid without the involvement
of the viral minor capsid proteins, VP2 and VP3. JCV
VLPs can be generated by recombinant JCV VP1 protein
in yeast expression. The recombinant VLPs were demon-
strated to be able to package and deliver exogenous DNA
into mammalian cell [5,6].
Patients with SLE produce large amounts of IL-10 in
their serum which correlate with disease activity [7,8].
Administration of IL-10 antagonists has been found to be
beneficial in the management of human SLE [9] or its
murine [10,11]. The decrease in IL-10 level may contrib-
ute to the amelioration of the disease symptoms. Thus,
IL-10 appears to play a key role in the autoimmune
responses and might serve as a therapeutic target for SLE.
In this study, we show that JCV VLPs can be used as a
gene delivery vector for IL-10 RNAi and for the possibil-
ity of gene therapy in SLE in the future.
Methods
Cell culture
The murine macrophage RAW 264.7 cell line was grown
in 90% DMEM and 10% fetal bovine serum (FBS)
obtained from Gibco BRL (Grand Island, NY) at a tem-
perature of 37°C under a humidified and 5% CO2 atmo-
sphere.
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Cells were counted using the trypan blue exclusion assay.
The extent of cell viability was calculated and the viable
cell numbers from experiment groups were compared
with those in the untreated control groups.
JC virus (JCV) virus-like particles (JCV VLPs)
JCV VLPs were generated by recombinant JCV VP1 pro-
tein in yeast expression system [12]. VLPs were further
purified by sucrose gradient (10-30%) centrifugation for
40 min at 35,000 rpm. Particle-containing fractions were
analyzed by hemagglutination activity after dialyzis in
Tris buffer. VLPs were concentrated by ultracentrifuga-
tion for 3 h at 35,000 rpm and resuspended in 100 μl PBS.
Construction of shRNA templates of IL-10
Two target sites were selected from mouse IL-10
(NM_000572) cDNA for generating two short hairpin
RNA (shRNA) templates. Sequences for the target sites
are GCTTCCAAACTGGATATAA and GTCTTCTG-
GAGTTCCGTTT respectively. For each shRNA tem-
plate, two oligonucleotides containing partial
complementary sequence of the shRNA with an overlap-
ping loop region were synthesized and annealed as a
shRNA cassette. The shRNA cassette was inserted into
pcDNA/HU6 vector and introduced into E. coli[13]. The
HU6-shRNA DNA fragment was polymerase chain reac-
tions (PCR) amplified by a set of primers on the vector of
flanking the HU6-shRNA template. Oligonucleotides
used for target site #1 (target site sequences are in bold).
IL10-RNAi-1-Forward: 5'-GATCCGCTTCCAAACTG-
GATATAATTCAAGAGAT; IL10-RNAi-1-Reverse: 5'-
AGCTTAAAAAAGCTTCCAAACTGGATATAATCTC
TTGAAT'; Oligonucleotides used for target site #2 (tar-
get site sequences are in bold); IL-10 RNAi-2-Forward: 5'-
GATCCGTCTTCTGGAGTTCCGTTTTTCAAGAGA
A; IL10-RNAi-2-Reverse: 5'-AGCTTAAAAAAGTCTTC
TGGAGTTCCGTTTTCTCTTGAAA.
Packaging shRNA into JCV VLPs
Briefly, 100 μg of purified JCV-VLPs were mixed with 1
μg of PCR amplified shRNA template in capsid buffer
(150 mM NaCl, 10 mM Tris-HCl, 0.01 mM CaCl2) and
was incubated for 10 min at 37°C. Osmotic shock was
achieved by diluting the mixture with 350 μl of distilled
water and incubated for 20 min at 37°C [14].
VLPs with IL-10 shRNA template or pEGFP-N3 for RAW264.7 
cells
RAW 264.7 cells were grown on cover slips in 35-mm
dishes overnight with DMEM supplement with 10% fetal
calf serum. Cells were washed with PBS and incubated
with 10 μg of VLPs containing the shRNA or pEGFP-N3
for 1 h at 37°C. Cells were then washed with PBS three
times. Complete DMEM was added to the culture and
incubated at 37°C with 5% CO2 for 48 h [14].
Real-time PCR
All studies were carried out in a designated PCR clean
area. RNA was extracted from cells using a Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer's instructions. Total RNA was isolated from the
RAW 264.7 cells incubated with LPS or VLPs with IL-10
shRNA. RNA samples were resuspended in diethyl pyro-
carbonate (DEPC)-treated water, quantified, and then
stored at -80°C until used. RNA concentration and purity
were determined by a spectrophotometer by calculating
the ratio of optical density at wavelengths of 260 and 280
nm. The first-strand of cDNA for RT-PCR was synthe-
sized from the total RNA (2 μg) using the Promega RT-
PCR system (Promega, Madison, Wisconsin, USA). The
cDNA was denatured for 10 min at 95°C. Specific DNA
fragments were amplified with a Max3000p Stratagene
cycler with 40 cycles of 15 s at 95°C, 60 s at 60°C and 30 s
at 72°C. The oligonucleotide primers were as follows: for
mouse IL-10, 5'-CACTACCAAAGCCACAAAGCA-3'
(forward) and 5'-AGGAGTCGGTTAGCAGTATGTT-3'
(reverse). The amount of amplified DNA fragments
encoding IL-10 was normalized to that of fragments
encoding 18 s rRNA. Results are presented as the 'relative
expression' in gene expression.
Animals
Six-week-old female BALB/c mice were obtained from
the National Animal Center, Taipei, Taiwan. The mice
were divided into four groups with the treatment of PBS,
LPS, LPS-VLPs-irrelevant shRNA and LPS-VLPs-IL-10
shRNA. LPS was from E. coli (Sigma Chemical Co. st.
Louis, MO, USA; serotype 0111: B4). The animal experi-
ments were approved by the Animal Research Committee
of Chung Shan Medical University, Taiwan.
IL-10 shRNA in BALB/c mice
Groups of BLAB/c mice were intraperitoneally injected
with a single dose of 25 μg of LPS in 100 μl PBS. After two
hours, mice were introvenousely treated with 250 μg of
JCV VLPs with IL-10 shRNA, or irrelevant shRNA,
respectively. After 6, 12 and 24 h of treatments, serum
samples were collected and tested for IL-10 and TNF-α
levels by real-time PCR and cytokine enzyme-linked
immunosorbent assay (ELISA).
Cytokine enzyme-linked immunosorbent assay (ELISA)
Conditioned RAW 264.7 cells medium and mouse serum
were collected for subsequent analysis of cytokines,
respectively. The levels of IL-10 and TNF-α were ana-
lyzed by using cytokines specific ELISA kits (IBL Co. Ltd,
Gunma, Japan).
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Statistical analysis was performed using the paired t-test.
A statistically significant difference was considered to be
present at P < 0.05.
Results
Purification of JCV virus-like particles (VLPs)
Recombinant JCV VLPs protein in yeast cells was puri-
fied and identified by SDS-PAGE (Fig. 1A) and Western
blot (Fig. 1B) using the rabbit antibody to JCV VLPs. The
JCV VLPs showed strong hemagglutination activity and
the activity was completely inhibited by JCV-positive
human serum. As the control, RAW 264.7 cells were
pseudoinfected with VLPs (Fig. 1C (I)), VLPs packaged
with pEGFP-N3 were analyzed by light microscopy (Fig.
1C (II)) and fluorescence microscopy (Fig. 1C (III)). All
RAW 264.7 cells transfected with VLPs expressed green
fluorescence (Fig. 1C (III)).
Suppression of IL-10 expression by IL-10 shRNA in RAW 
264.7 cells
Two preparations of IL-10 shRNA (IL-10i-1 and IL-10i-2)
were packaged into JCV VLPs by osmotic shock and were
confirmed by PCR (Fig. 2A). The morphology of RAW
Figure 1 Purification of JCV virus-like particles (VLPs). Recombinant JCV VLPs protein in yeast cells was purified and identified by SDS-PAGE (A) 
and Western blot (B). Lane M: molecular weight marker; Lane VLPs: JCV virus-like particles. The rabbit antibody reactive to the JC virus-like particle is 
indicated by an arrow. (C) RAW 264.7 cells were pseudo-infected with VLPs packaged with pEGFP-N3 (II, III) and were analyzed by light microscopy (II) 
and fluorescence microscopy (III). Light microscopy of RAW 264.7 cells with pseudo-infected with VLPs as a control (I).
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was shown in Fig. 2B. The cells with the pseudoinfection
of VLPs were stained with DAPI (Fig. 2B) and the cell via-
bility was detected by trypan blue staining (Fig. 2C). Fig-
ure 3 shows suppression of IL-10 expression in RAW
264.7 cells. Both IL-10i-1 and IL-10i-2 could reduce IL-10
expression about 85% and 89%, respectively, by real-time
PCR compared to VLPs only (Fig. 3A) (p < 0.005). The
expression of TNF-α was not affected by IL-10 shRNA
treatment (Fig. 3B). The suppression of IL-10 by IL-10
shRNA was dose-dependent (Fig. 3C). Figure 3(D) shows
the suppression of IL-10 by IL-10 shRNA after LPS stim-
ulation in RAW 264.7 by real-time PCR. The irrelevant
shRNA did not suppress the production of IL-10. The IL-
10 shRNA packaged in JCV VLPs could sufficiently sup-
press IL-10 expression in RAW 264.7 cells. We also found
that the expression of TNF-α was not affected by IL-10
shRNA after LPS treatment in RAW264.7 cells by ELISA
(Fig. 3E). Figure 3F shows reduction of IL-10 by IL-10
shRNA after LPS treatment in RAW 264.7 cells at 36 and
48 hours by ELISA. In addition, the IL-10 suppressive
effects could be sustained for 48 h by IL-10 shRNA. Thus,
we found suppression of IL-10 by VLPs-IL-10 shRNA not
only at mRNA levels but also at protein level.
Effects of IL-10 shRNA on cytokines production of IL-10 and 
TNF-α in BALB/c mice
After LPS treatment in mice, IL-10 was increased and the
peak concentration of IL-10 was at 6 h then decreased at
Figure 2 Effects of VLPs IL-10 shRNA on morphology and viability of RAW 264.7 cells. (A) Two preparations of IL-10 shRNA (IL-10i-1 and IL-10i-
2) were packaged into JCV VLPs by osmotic shock. The presence of IL-10 shRNA template in VLPs was confirmed by PCR. Lane 1: VLPs; Lane 2: JCV VLPs 
with IL-10i-1 shRNA template; Lane 3: VLPs; Lane 4: VLPs with IL-10i-2 shRNA template. (B) RAW 264.7 cells were pseudo-infected with VLPs packaged 
with IL-10 shRNA and the effects of cell apoptosis were determined by 2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) staining. (C) 
Cell viability was determined by trypan blue staining. VLPs IL-10 shRNA, VLPs only, or shRNA only did not induce cell death.
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shRNA treatment, IL-10 was also increased at 6 h, but the
peak concentration was delayed to 12 h. The concentra-
tion of IL-10 was higher in the group of mice treated with
LPS-irrelevant shRNA than these with LPS only treat-
ment (Fig. 4). The irrelevant shRNA itself could obviously
induce IL-10 production. The production of IL-10 was
decreased after VLPs with IL-10 shRNA treatment (93%
of suppression) (P < 0.05). There was no suppression of
IL-10 in the control groups treated with PBS, LPS and
LPS-VLP-irrelevant shRNA.
Effects of TNF-α
TNF-α was also increased after LPS injection and the
peak concentration of TNF-α was at 24 h. TNF-α was
increased in the groups with LPS and LPS-irrelevant
shRNA treatment. The concentration of TNF-α was
decreased after JCV VLPs IL-10 shRNA treatment (81%
of suppression) (Fig. 4). IL-10 shRNA did not cross-react
with TNF-α mRNA and influence the expression of TNF-
α in RAW 264.7 cells (Fig. 3B). In BALB/c mice, however,
down regulation of IL-10 by IL10 shRNA could affect
TNF-α expression (Fig. 4).
Effects on survival
All mice treated with PBS only or LPS-VLPs-IL-10
shRNA survived in the end of the experiment, but all
mice treated with LPS only or LPS-VLPs irrelevant
shRNA died after 24 h of treatment. The mice treated
with LPS-VLPs-IL-10 shRNA had longer lifespan than
those treated with LPS-VLPs irrelevant shRNA or LPS.
(Fig. 5)
Discussion
We have shown for the first time that JCV VLPs could be
used as a vector to deliver IL-10 shRNA in both RAW
Figure 3 Suppression of IL-10 expression in RAW 264.7 cells by two IL-10 shRNA preparations. Cells were cultured with either IL-10 shRNA (IL-
10i-1 or IL-10i-2) or irrelevant shRNA for 24 h. After washing, gene expression was analyzed by real-time PCR. Represented are the mRNA levels of target 
gene relative to those of 18 s rRNA. (A) Suppression of IL-10 expression was analyzed by real-time PCR. (B) IL-10 shRNA did not cross-react with TNF-α 
mRNA and influence the expression of TNF-α in RAW 264.7 cells. Relative TNF-α expression was analyzed by Real-time PCR. (C) Suppression of IL-10 
expression by various doses of IL-10 shRNA in RAW 264.7 cells. (D) RAW 264.7 cells (2 × 105) were pre-treated with LPS (2 μg/ml) for 90 min. Cells were 
then cultured with either IL-10 shRNA (IL-10i-2) or irrelevant shRNA for 24 h. After washing, IL-10 expression was analyzed by real-time PCR. Represent-
ed are the mRNA levels of IL-10 relative to those of 18 s rRNA. *: P < 0.05; ***: P < 0.005. (E) RAW 264.7 cells (2 × 105) were pre-treated with LPS (2 μg/
ml) for 90 min. Cells were then cultured with either IL-10 shRNA (IL-10i-2) or irrelevant shRNA for 36 h. After 36 h, conditioned medium was collected 
for analysis of TNF-α expression by ELISA. (F) RAW 264.7 cells (2 × 105) were pre-treated with LPS (2 μg/ml) for 90 min. Cells were then cultured with 
either IL-10 shRNA (IL-10i-2) or irrelevant shRNA for 0, 6, 12, 24, 36, 48 and 60 hours. After 0, 6, 12, 24, 36, 48 and 60 hours, conditioned medium was 
collected for analysis of IL-10 expression by ELISA. *: P < 0.05.
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shRNA could effectively silence the IL-10 cytokine both
in vitro and in vivo and were not toxic to RAW 264.7 cells.
These findings suggest that JCV VLPs is an effective
delivery vector for RNAi delivering with potentially ther-
apeutic use for autoimmune diseases such as SLE.
Among methods for gene transfer into cells, viral gene-
delivery system is a most effective method. In previous
studies, we demonstrated that the recombinant JC virus
major capsid protein, VP1, is able to self-assemble to
form a virus-like particle (VLP) when expressed in the
baculovirus [4], E. coli [14] and yeast [12]. In addition, the
VLP is able to package exogenous DNA and deliver it into
human kidney [14], glioma [5] and colon adenocarci-
noma [15] cells. These findings indicate that the JCV
VLPs may be used as a gene delivery vector for therapeu-
tic applications. In addition, JCV VLPs may be used for
human therapy [15]. In this study, we further extended
the findings that JCV VLPs provided an efficient tool for
delivering shRNA to silence the targeted RNA. Because
of lack of viral nucleic acids in JCV VLPs, JCV do not
cause serious risks for infection and are considered as a
safe and efficient method for transfection of RNAi. The
JCV receptor is widely distributed among mammalian
cells including human, monkey, and mouse. JCV can
enter a wide variety of cell types [16]. However, the
immune response is a limitation when developing a viral
gene delivery vectors. For human polyomaviruses, most
adults are seropositive against JCV. It may not beneficial
to use the JCV VLPs as a gene delivery vector in such cir-
cumstances. Therefore, modification of the JCV VLPs to
avoid immune elimination may be useful in advancing the
development of the JCV as a gene delivery vector in
human.
We used the HU6-shRNA template for expressing
RNAi. Since VLPs has a certain DNA packing capacity, to
increase the ratio of packed shRNA template, a minimal
linear DNA fragment containing HU6 promoter and
shRNA template (HU6-shRNA template) was PCR ampli-
fied and packed into VLPs. This linear HU6-shRNA tem-
plate was efficiently packed into VLPs and expressed
successfully in cells and animals. Other than more eco-
Figure 4 In vivo effects of IL-10 shRNA on production of IL-10 and TNF-α in BALB/c mice. Groups of BALB/c mice were intraperitoneally injected 
with LPS (25 μg). After two hours, mice received VLPs-IL-10 shRNA or irrelevant shRNA intravenously. After 6, 12, 24 and 36 h, serum samples were 
collected from each mouse and tested for IL-10 and TNF-α levels by ELISA. The level of IL-10 was suppressed after the treatment of IL-10 shRNA. *: P < 
0.05; ***: P < 0.005.
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is that the shRNA can be synthesized continuously as
long as the DNA template exists, while siRNA will be
cleaved along with target mRNA degradation.
In this study, we used two IL-10 shRNAs which target
different sites of IL-10 in RAW264.7 cells and found that
both IL-10 shRNAs efficiently reduced IL-10 mRNA but
not TNF-α mRNA level (Fig 3. B). We have two reasons to
believe that there is no cross reaction between IL-10
shRNA and TNF-α mRNA. First, both IL-10 shRNAs did
not affect TNF-α mRNA level. Second, since RNAi is
mainly functioning on mRNA level of target gene and
real-time PCR is a sensitive method to quantitate the
level of mRNA, we are confident that IL-10 shRNA did
not react with TNF-α mRNA. However, down regulation
of IL-10 via shRNA is accompanied by reduction of TNF-
α level in an animal model (Fig. 4). This could be
explained by the possibility that down regulation of IL-10
may affect TNF-α expression in other cell types through
paracrine system.
Toxic shock is mediated by a complex set of cytokine
interactions. Previous studies showed that infusion of
LPS mimics the endotoxic state and results in the produc-
tion of multiple inflammatory cytokines, including IL-1,
INF-γ and TNF-α production, which is known to cause
tissue necrosis and organ failure. In addition to inducing
the production of pro-inflammatory cytokines, LPS also
triggers the release of anti-inflammatory cytokines, such
as IL-10, in the bloodstream of normal mice [17]. Many
cell types can produce IL-10, including phagocytic cells,
conventional DCs, T cells, B cells, and NK cells. IL-10 has
been implicated as a key anti-inflammatory modulator in
Figure 5 Outcome of BALB/c mice treated with LPS, irrelevant shRNA and IL-10 shRNA. Groups of BALB/c mice were intraperitoneally injected 
with LPS (25 μg). After two hours, mice received intravenously VLPs-IL-10 shRNA and irrelevant shRNA. The survival rate and survival time of the animals 
were observed and compared between groups.
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critical counterbalance to proinflammatory cytokine syn-
thesis. It acts to terminate the inflammatory response and
limit inflammation-induced tissue pathology by deacti-
vating macrophages and silencing their synthesis of TNF-
α, IL-6, IL-1α, IL-8, and an array of other proinflamma-
tory cytokines and chemokines. In mouse models of toxic
shock, IL-10 is produced very rapidly after exposure to
LPS [18,19] and serum levels of INF-γ and IL-10 peak at
the same time as TNF-α, which is known to play a central
role in the pathogenesis of toxic shock. In such models, it
was observed that IL-10 appears in the serum within one
hour after LPS challenge and persists in the blood for at
least six hours [18,19]. Subsequently, it was found that a
single injection of IL-10 prevented death in murine mod-
els of LPS-induced toxic shock, and maximum protection
was afforded only when IL-10 was given shortly before or
after IL-10 challenge [18,20]. Neutralization of endoge-
nously produced IL-10 by administration of anti-IL-10
monoclonal antibody 2 h before LPS challenge resulted in
a marked increase in both TNF-α and IFN-γ serum levels,
and high mortality rates [19], suggesting that the rapid
release of IL-10 during endotoxemia is a natural antiin-
flammatory response controlling cytokine production
and LPS toxicity. Increased lethality was also observed
when anti-IL-10 antibody treatment was given at the
same time as LPS [19,21], but not when the antibody
treatment was delayed until 3 hours after challenge [21],
suggesting that IL-10 mediates protection in the earliest
phase of the LPS response. In the current study, the anti-
IL-10 shRNA was administered to mice two hours after
LPS injection. This could explain, only in part, the benefi-
cial effects on survival we have observed.
Another potential explanation stems from the complex-
ity of functions played by IL-10 in the immune system.
Although IL-10 is considered a potent antiinflammatory
cytokine, studies have suggested that IL-10 also possesses
immunostimulatory effects [22,23]. When administered 1
h after LPS injection, it potentiated LPS-induced IFN-
release, which was associated with elevated levels of the
IFN-dependent chemokines. In addition, IL-10 treatment
enhanced activation of CTL and NK cells after LPS injec-
tion. Since, under certain conditions, IL-10 has proin-
flammatory functions in vivo, stimulating CD4+, CD8+ T
cells, and/or NK cells, it is possible that the anti-IL-10
shRNA used in the current work blocked profoundly IL-
10 production in several cell types, leading to less inflam-
mation and lower mortality rates in mice exposed to toxic
shock.
In this study, BALB/c mice treated with IL-10-VLPs-
shRNA decreased production of IL-10 (93% suppression).
This finding provides a good model using JCV VLPs as a
delivery tool for RNAi in vivo. IL-10 is a key regulator of
the immune system and has been reported to be associ-
ated the development of SLE. The decrease in the expres-
sion level of IL-10 may contribute to the amelioration of
the disease symptoms in human SLE [9]. It has been
reported that treatment with anti-IL-10 antibody delayed
onset of autoimmunity in (NZW/NZB)F1 mice and led to
a reduction in disease activity [10,11]. RNAi offers the
prospects of higher specificity, lower immunogenicity,
and greater disease modification than current antibody
therapies.
In conclusion, JCV VLPs is an easily prepared agent
capable of effectively delivering RNAi in vitro and in vivo
without significant cytotoxicity. The system provides an
efficient tool for delivering the RNAi for the possibility of
gene therapy in the future.
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